Stoke Therapeutics announced that it has not reached an agreement with the Food and Drug Administration (FDA) regarding an expedited submission for its severe epilepsy treatment, zorevunersen. The company revealed this development on Sunday, following a meeting in December 2023. The FDA has not dismissed Stoke’s request to submit zorevunersen, which targets Dravet syndrome, earlier than the completion of an ongoing Phase 3 study scheduled for mid-2027.
Ian Smith, CEO of Stoke Therapeutics, shared insights in an interview, indicating that while the FDA requested additional information from the company, future discussions are planned. The FDA’s response does allow for the possibility of an earlier submission, reflecting a degree of flexibility in their review process.
Next Steps for Stoke Therapeutics
Stoke Therapeutics aims to determine its regulatory strategy for zorevunersen by mid-2024. The company is currently assessing the data and feedback from the FDA to guide its next steps. This decision is critical for Stoke, as zorevunersen represents a potential breakthrough for patients suffering from Dravet syndrome, a severe form of epilepsy.
Dravet syndrome affects approximately one in 15,700 infants and is characterized by frequent, prolonged seizures that can lead to developmental delays and other serious health issues. The need for effective treatments is pressing, making the FDA’s eventual decision particularly significant for both Stoke and the families affected by this condition.
As the situation develops, Stoke Therapeutics will remain in close contact with the FDA to provide the requested additional information. The outcome of these discussions will be crucial in shaping the timeline for zorevunersen’s potential availability on the market.
Stoke’s pursuit of an expedited pathway signifies the broader challenges faced by biotech companies in navigating the regulatory landscape. The company is committed to ensuring that it meets all necessary requirements while striving to deliver innovative treatments to patients in need.
